Exelixis (EXEL) Tops Q4 EPS by 9c
Tweet
Share
E-mailGet Alerts EXEL Hot Sheet
EPS Growth %: +13.3%
Financial Fact:
Net loss: -37.02M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Exelixis (NASDAQ: EXEL) reported Q4 EPS of $0.14, $0.09 better than the analyst estimate of $0.05. Revenue for the quarter came in at $270 million versus the consensus estimate of $262.14 million.
GUIDANCE:
Exelixis sees FY2021 revenue of $1.15-1.25 billion, versus the consensus of $1.2 billion.
Net product revenues |
| $950 million - $1,050 million |
Cost of goods sold |
| Approximately 5% - 6% of net product revenue |
Research and development expenses (1) |
| $600 million - $650 million |
Selling, general and administrative expenses (2) |
| $375 million - $425 million |
Effective tax rate |
| 20% - 22% |
Cash and investments (3) |
| $1.6 billion - $1.7 billion |
(1) | Includes $45 million of non-cash stock-based compensation expense. | |
(2) | Includes $60 million of non-cash stock-based compensation expense. | |
(3) | This cash and investments guidance does not include any potential new business development activity. |
For earnings history and earnings-related data on Exelixis (EXEL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
- SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
